• Loading stock data…

Eurobio Scientific launches new proprietary test for the detection of Omicron BA.x, BA.2 and Delta variants of SARS-CoV-2

Last Updated on March 9, 2022 by GlobeNewsWire

Eurobio Scientific launches new proprietary test for the detection of Omicron BA.x, BA.2 and Delta variants of SARS-CoV-2

Routine COVID screening test that simultaneously detects and identifies the presence of Omicron BA.x, Omicron BA.2 and screens for other Delta variantsFirst French test for screening for Omicron and Delta variants requiring only one reaction and delivering a result in 45 minutes

Paris, March 9, 2022 – 18:15 pm

Eurobio Scientific (FR0013240934, ALERS, PEA-PME eligible), a leading French group in specialty in vitro medical diagnostics, announces the RUO (Research Use Only) launch of a new proprietary test, EBX 048, Eurobioplex SARS-CoV-2 Fast-SVT (Screening and VOC1 Typing), developed specifically for routine COVID-19 screening and identification of current variants.

The proprietary EBX SARS-CoV-2 Fast-SVT is a real-time polymerase chain reaction (RT-PCR2) assay that, in a single test, identifies the presence of the SARS-CoV-2 virus and detect the K417N (Omicron variant BA.x sublineage screening), V213G (Omicron variant BA.2 sublineage screening) and L452R (Delta variant screening) mutations in a qualitative manner. The presence of the V213G mutation thus allows the BA.2 sublineage to be differentiated from other sublineages of the Omicron variant.

This new test, designed and developed by Eurobio Scientific’s R&D department, is produced in-house, in its premises in Les Ulis – France and follows the ISO 13485 regulatory process. It is available in several versions allowing 50, 100 or 200 determinations to be performed simultaneously.

EBX SARS-CoV-2 Fast-SVT is immediately available for hospital and private laboratories, both in France and internationally in its RUO version.

Next financial meeting

2021 annual results: 6 April 2022, (after market close)

This press release contains elements that are not historical facts including, without limitation, certain statements about future expectations and other forward-looking statements. Such statements are based on management’s current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, profitability or events to differ materially from those anticipated. In addition, Eurobio Scientific, its shareholders, and its affiliates, directors, officers, advisors and employees have not verified the accuracy of, and make no representations or warranties in relation to, statistical data or predictions contained in this press release that were taken or derived from third party sources or industry publications. Such statistical data and predictions are used in this press release for information purposes only. Finally, this press release may be drafted in the French and English languages. If both versions are interpreted differently, the French language version shall prevail.

About Eurobio Scientific

Eurobio Scientific is a key player in the field of specialty in vitro diagnostics. It is involved from research to manufacturing and commercialization of diagnostic tests in the fields of transplantation, immunology and infectious diseases, and sells instruments and products for research laboratories, including biotechnology and pharmaceutical companies. Through many partnerships and a strong presence in hospitals, Eurobio Scientific has established its own distribution network and a portfolio of proprietary products in the molecular biology field. The Group has approximately 164 employees and three production units based in the Paris region, in Germany and in the United States, and several affiliates based in Dorking UK, Sissach Switzerland, Bunde Germany and Utrecht in The Netherlands.

For more information, please visit : www.eurobio-scientific.com
The company is publicly listed on the Euronext Growth market in Paris
Euronext Growth BPI Innovation, PEA-PME 150 and Next Biotech indices, Euronext European Rising Tech label.

Symbol: ALERS – ISIN Code: FR0013240934 – Reuters: ALERS.PA – Bloomberg: ALERS:FP

1 VOC : Variant of Concern
2 The “Polymerase Chain Reaction” (PCR) is a method based on the selective multiplication of target DNA sequences, which makes it possible to detect specific DNA sequences present in a product.



Print Friendly, PDF & Email
Spread the word

Reader Interactions

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Generated by Feedzy
%d bloggers like this: